Double Medical 2026H1: Dental business revenue approximately RMB 40.24 million, up 14.90% year-on-year.

Source: Double Medical 2026 Semi-Annual Report

Net Profit Attributable to Shareholders of the Parent Company: RMB 353 million (+44.65% YoY) / Operating Revenue: RMB 1.340 billion (+10.69% YoY) / Sports Medicine Revenue Up 72.50%

DentalGoodNews｜August 27, 2026, Double Medical Technology Inc. (hereinafter referred to as "Double Medical") released its 2026 semi-annual report. During the reporting period, the company achieved operating revenue of RMB 1.340 billion, a year-on-year increase of 10.69%; net profit attributable to shareholders of the listed company (hereinafter referred to as "net profit attributable to shareholders of the parent company") reached RMB 353 million, up 44.65% year-on-year. Basic earnings per share stood at RMB 0.8648, up 43.97% year-on-year; weighted average return on equity was 9.43%, up 1.83 percentage points year-on-year.

During the period, the company's net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, was RMB 279 million, up 25.10% year-on-year. Net cash flow from operating activities was RMB 276 million, up 4.87% year-on-year. During the reporting period, the company's overall gross margin was 74.45%, up 3.44 percentage points from the same period last year. Compared with the same period in 2025, the company's growth pace has shifted: in the first half of 2025, operating revenue and net profit attributable to shareholders of the parent company grew 25.55% and 76.69% year-on-year, respectively; in the first half of 2026, the growth rates of these two indicators moderated to 10.69% and 44.65%.

Source: Double Medical 2026 Semi-Annual Report

Regarding dental-related business, Double Medical achieved operating revenue of RMB 40.2362 million in the first half of the year, up 14.90% year-on-year, accounting for 3.00% of total revenue. According to previous reports by DentalGoodNews, Double Medical's dental product revenue in 2025 was RMB 71 million, and this semi-annual report data continues the growth momentum of this business segment.

By region, the company's domestic market generated revenue of RMB 1.183 billion, up 12.41%; overseas market revenue was RMB 156 million, a slight decrease of 0.75% year-on-year, with the overseas revenue share adjusting from 13.02% in the same period last year to 11.67%. As of June 30, 2026, the company and its subsidiaries had obtained 1,315 medical device registration certificates and held 923 valid patents.

Source: Double Medical 2026 Semi-Annual Report

In terms of expenses, during the reporting period, the company's operating costs were RMB 342 million, down 2.45% year-on-year; selling expenses were RMB 351 million, up 8.77% year-on-year; administrative expenses were RMB 68.5503 million, down 13.25% year-on-year; R&D investment was RMB 168 million, up 4.84% year-on-year; financial expenses were a net income of RMB 3.0387 million, compared with a net expenditure of RMB 24.0489 million in the same period last year; income tax expenses were RMB 59.2130 million, up 49.91% year-on-year, mainly due to the increase in total profit for the period, which correspondingly increased income tax expenses. In addition, net cash flow from investing activities was -RMB 147 million, compared with -RMB 97 million in the same period last year, mainly due to increased purchases of wealth management products during the period; net cash flow from financing activities was -RMB 143 million, narrowing by 53.99% year-on-year, mainly due to the deferral of dividend payments to July of the current period.

The company's net assets attributable to shareholders of the parent company stood at RMB 3.517 billion, a slight decrease of 1.50% from the end of the previous year. This change primarily stems from two equity-related expenditures: first, in July 2026, the company implemented its 2025 annual profit distribution plan, distributing a cash dividend of RMB 6 (tax inclusive) per 10 shares, totaling approximately RMB 243 million; second, the company continued to advance its share repurchase plan, cumulatively repurchasing 4,493,407 shares through centralized auction trading during the reporting period, accounting for 1.0853% of total share capital, with a repurchase amount of approximately RMB 185 million, recorded as treasury stock and offset against shareholders' equity.